Join us for a Medscape LIVE! symposium focusing on the best practices for managing intermediate-risk and high-risk non-muscle invasive bladder cancer (NMIBC). Our expert faculty will discuss optimal management of patients with intermediate and high risk NMIBC, including current challenges in these patient populations and emerging therapeutic options. Neoadjuvant intravesical therapy in NMIBC will also be discussed. We look forward to seeing you there!
The goal of this activity is to educate physicians on the latest recommendations regarding the management of intermediate-risk and high-risk NMIBC.
Upon completion of this activity, participants will: Have greater competence related to: [list][item]Looking at the different considerations made when selecting the most optimal treatment modality for patients with intermediate-risk NMIBC [item]Selecting the most optimal treatment strategy for patients with high-risk NMIBC [/list]Demonstrate greater confidence in their ability to: [list][item]Apply best practices in the management of intermediate-risk and high-risk NMIBC [/list]
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD). [WEBMDGLOBALLOGO]